SCHEMBL58247

SCHEMBL58247

CC(c1cc([N+](=O)[O-])ccc1S(=O)(=O)O)C1CO1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
HPGD P15428 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MCOLN3 Q8TDD5 1/20 0.40
NT5E P21589 2/20 0.40
CYP2C19 P33261 2/20 0.39
TSHR P16473 1/20 0.39
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
CYP3A4 P08684 2/20 0.35
PDE2A O00408 1/20 0.35
PDE5A O76074 1/20 0.35
ALOX15 P16050 1/20 0.35
NFKB1 P19838 1/20 0.35
APEX1 P27695 1/20 0.35
PDE4A P27815 1/20 0.35
BLM P54132 1/20 0.35
PDE1B Q01064 1/20 0.35
PMP22 Q01453 1/20 0.35
PDE4B Q07343 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9099849 0.81 NT5E (0.47) ALDH1A1HPGDNPSR1MCOLN3NT5E
SCHEMBL9099856 0.81 NT5E (0.47) ALDH1A1HPGDNPSR1MCOLN3NT5E
SCHEMBL3899543 0.78 ALDH1A1 (0.48) ALDH1A1CYP3A4ALOX15L3MBTL1SMN1; SMN2
SCHEMBL9098078 0.74 KMT2A (0.45) ALDH1A1HPGDNT5ECYP2C19CYP3A4
SCHEMBL10477956 0.72 PRMT5 (0.46) ALDH1A1NT5ECYP2C19TSHRPRMT5
SCHEMBL16052639 0.72 PRMT5 (0.46) ALDH1A1NT5ECYP2C19TSHRPRMT5
SCHEMBL27961962 0.72 NT5E (0.42) ALDH1A1HPGDNPSR1MCOLN3NT5E
SCHEMBL10477957 0.72 PRMT5 (0.46) ALDH1A1NT5ECYP2C19TSHRPRMT5
SCHEMBL58848 0.72 KMT2A (0.39) ALDH1A1SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL468316 0.70 ALDH1A1 (0.58) ALDH1A1NT5ECYP2C19TSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107406386-B Process for producing 1- (4-hydroxyphenyl) -4- (4-trifluoromethoxyphenoxy) piperidine or salt thereof 大塚制药株式会社 2021-06-01 CN disclosed
EP-2644599-B1 Method for preparing a 2-halo-4-nitroimidazole compound OTSUKA PHARMA CO LTD (JP) 2014-12-10 EP disclosed
EP-2644599-A1 Method for preparing 1-substituted-4-nitroimidazole compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-02 EP disclosed
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same OTSUKA PHARMACEUTICAL CO., LTD. 2012-05-24 US disclosed
US-8129544-B2 Preparation of 4-nitroimidazoles that are 2-substituted with a halo or optionally oxidized phenylthio group and 1-substituted with hydrogen, an oxiranylmethyl-, or a phenyl- group; dehalogenation, reduction, nitration, rearrangement OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-06 US disclosed
US-7807843-B2 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-05 US disclosed
US-20080200689-A1 1-Substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO., LTD. 2008-08-21 US disclosed
US-7368579-B2 1-substituted-4-nitroimidazole compound and process for producing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-05-06 US disclosed
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same OTSUKA PHARMACEUTICAL CO. LTD. 2008-04-24 US disclosed
US-20060079697-A1 1-substituted-4-nitroimidazole compound and process for producing the same OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-13 US disclosed
EP-1553088-A1 1-SUBSTITUTED 4-NITROIMIDAZOLE COMPOUND AND PROCESS FOR PRODUCING THE SAME Otsuka Pharmaceutical Company, Limited (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120130082-A1 1-Substituted-4-Nitroimidazole Compound and Method for Preparing the Same CBR1, CBR3, DCXR ALDH1A1 836/4885HPGD 1049/4885NPSR1 337/4885
US-20060079697-A1 1-substituted-4-nitroimidazole compound and process for producing the same CBR1, CBR3, DCXR ALDH1A1 780/4885HPGD 998/4885NPSR1 492/4885
US-20080200689-A1 1-Substituted-4-nitroimidazole compound and method for preparing the same CBR1, CBR3, DCXR ALDH1A1 836/4885HPGD 1049/4885NPSR1 337/4885
US-20080097107-A1 1-substituted-4-nitroimidazole compound and method for preparing the same CBR1, CBR3, DCXR ALDH1A1 836/4885HPGD 1049/4885NPSR1 337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.